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Nasopharyngeal carcinomas (NPC) are tumors of nasopharynx origin with high rate of distance 
metastases after radiotherapy. Therefore, detection of micrometastasis will be an important issue in the 
prognostic and the choice of the systemic treatment. Our aim was early detection of circulating tumor 
cells in the blood of NPC patients by an RT-PCR assay for cytokeratin19 mRNA. Patients and methods 
used are venous blood samples obtained from 30 NPC patients with biopsy-proven NPC and 20 healthy 
blood donors which were tested using a previously reported assay. Identity of products was confirmed 
by sequencing. Results obtained show that 10 of the 30 NPC were positive for CK19 transcripts in 
peripheral blood, suggesting the presence of tumour epithelial cells. No CK19 positive cells were 
detected in the 20 healthy volunteers. Nevertheless, we encountered the problem of CK19 pseudogene 
interference due to genomic DNA contamination of RNA preparations. Four of the 10 positive patients 
were proven to have CK19 mRNA, as assessed by sequencing. In the remaining six, the presence of the 
CK19 pseudogene may has masked the CK19 mRNA in RT-PCR and sequencing. In conclusion, we 
described an improved RT-PCR assay that is sensitive and has high clinical specificity to detect minimal 
metastatic disease in NPC patients. Nevertheless, one should be aware about the necessity to optimize 
the analytical specificity of the assay. 
 






Nasopharyngeal Carcinoma (NPC) is a rare tumor arising 
from the mucosal epithelium of the nasopharynx. It is 
vastly more common in South East Asia and North Africa 
than elsewhere (Chen et al., 2013). The majority of NPC 
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Patients present at the moment of diagnosis have occult 
or detectable metastases. Indeed, NPC is difficult to 
detect early due to the anatomical position of the 
nasopharynx, its symptoms that mimic those of many 
other conditions and its tendency to present with cervical 
lymph node metastases. Distant metastases to the liver, 
the lung or the bone marrow and locoregional recurrence 
to the nasopharynx and the neck are the main causes of 
mortatlity and therapeutic failure (Chen et al., 2013). 
Surgical or radiotherapy treatment controls only the 
primary tumor and does not prevent the appearance of 
distant metastases treated only by chemotherapy. 
Chemotherapy treatment is little efficient and not well 
tolerated by the patient. So, early detection of micro-
metastases and the prediction of recurrence will be an 
important issue in the prognostic of newly diagnosed 
NPC patients, in the choice of systemic treatment and in 
monitoring the effectiveness of the adjuvant therapy. 
To improve on existing methods of detection, we 
evaluated, using a nested reverse-transcriptase polyme-
rase chain reaction (RT-PCR) assay, the RNA transcript 
encoding for the intermediate filament protein cytokeratin 
19 (CK19), as a marker for circulating nasopharyngeal 
carcinoma cells in the blood of patients with NPC. Since 
this class of cytokeratin is expressed only in normal and 
malignant epithelial cells but is absent in hematopoietic 
tissues of healthy subjects, detection of CK19 transcript 
in the peripheral blood of patients with known NPC 
should indicate the presence of circulating nasopharyn-
geal carcinoma cells. 
 
 
MATERIALS AND METHODS 
 
Patients and tissue samples 
 
The study population consisted of 30 non apparent patients with 
biopsy-proven NPC (25 previously untreated and 5 were treated at 
the time of sample collection) admitted at Salah Azaiez Oncology 
Institute of Tunis, Tunisia; before blood sampling, all NPC patients 
received detailed staging work-up. Patient characteristics are 
shown in Table 1. In addition, 20 healthy volunteers admitted as 
bone marrow donors in the National Center for Blood Transfusion of 
Tunis were tested as negative controls. Informed consent was 
obtained from all subjects. 
 
 
Blood processing and RNA extraction 
 
From each patient, 8 ml of peripheral blood were collected in 15 ml 
heparin- rinsed tube. Before blood collection, an initial 3 ml of blood 
was discarded to avoid possible contamination by normal skin cells. 
Whole blood was centrifuged at 4000 rpm for 15 min. The cellular 
pellet was then subjected to the RNA extraction procedure using 
the acid guanine-phenol-chloroform technique, with TRIzole (Invi-
trogen), according to the manufacturer’s instructions. After isolation, 
the RNA pellet was suspended in 50 µl diethyl-pyrocarbonate 





0.6 µg of total cellular RNA was  reverse-transcribed in a 25 µl reac- 




tion mixture containing 5 units of avian myeloblastosis virus reverse 
transcriptase (AMV) (Promega), 10 mM Tris/HCl (pH 8.3), 10 mM 
KCl, 2 mM MgCl2, 0.1 mM spermidine, 2 mM dithiotreitol, 0.4 mM 
dNTP (Promega) and 25 µM oligo(dT)18. The reaction was 
performed with a denaturing step of the RNA template (5 min at 
90°C, snap cooled) followed by a synthesis step (1 h at 42°C). The 
reaction was terminated by heating at 92°C for 5 min. 
 
 
PCR amplification of β-actin transcripts 
 
In order to control the integrity of the extracted RNA and the quality 
of the first strand of the synthesized cDNA, all patients were tested 
for the presence of the β-actin RNA, a housekeeping gene 
expressed by all cells of the organism. The PCR mixture contained 
5 µl of the cDNA from the reverse transcription, 20 pmol of each β-
actin primers (sense: CACTGTGTTGGCGTACAGGT, anti-sense: 
TCATCACCATTGGCAATGAG), 10 mM Tris-HCl (pH 8.8), 50 mM 
KCl, 1.5 mM MgCl2, 10 mM dNTP and 2.5 units of Go Taq DNA 
polymerase (Promega) in a total volume of 50 µl. PCR was 
performed with the following conditions: initial denaturation at 95°C 
for 5 min, followed by 40 cycles at 94°C for 40 s, 54°C for 1 min, 
and 72°C for 50 s, followed by a final extension at 72°C for 10 min. 




PCR amplification of CK-19 transcripts 
 
We evaluated the RNA transcript encoding for CK-19 as a marker 
for epithelial cells using a specific RT-PCR-based assay described 
by Lin et al. (2000). To increase the sensitivity of this assay, the 
primary amplified product was subjected to a nested PCR. In order 
to exclude amplification from the genomic DNA, both outer and 
inner primer pairs were selected from two different exons and one 
of the outer primer pairs was located across the junction of exon-
intron (Figure 2). The first round of the PCR was performed using 5 
µl of the cDNA as template. The PCR mixture contained 20 pmol of 
each CK-19 outer primers (sense: 
ACCATGAGGAGGAAATCAGTAC, antisense: 
ATCTTCCTGTCCCTCGAGCA), 10 mM Tris-HCl (pH 8.8), 50 mM 
KCl, 1.5 mM MgCl2, 10mM dNTP and 2.5 units of  Go Taq DNA 
polymerase in a total volume of 50 µl. The PCR program included 1 
cycle at 94°C for 5 min, and 40 cycles consisting of 40 s at 94°C, 1 
min at 60°C and 50 s at 72°C. Finally, an extension at 72°C for 10 
min. For the second round of amplification, 5 µl of the first round 
PCR product was added to 20 pmol of each CK19 inner primers 
(sense: CCAAGATCCTGAGTGACATGCGAAG, anti-sense: 
GATGTCCATGAGCCGCTGGTAC), 10 mM Tris/ HCl (pH 8.8), 50 
mM KCl, 1.5 mM MgCl2, 10 mM dNTP and 2.5 units of Go Taq DNA 
polymerase (Promega) in a total volume of 50 µl. The second PCR 
was carried out under the same conditions as the first PCR. 
The PCR products were electrophoresed on a 2% agarose gel 
and analyzed by direct visualization under UV after ethidium 
bromide staining. The presence of a 518-bp first round product or a 
371-bp second-round product indicated the presence of CK19 
transcripts. All positive CK19 positive RT-PCR assays were 
repeated from a second aliquot of RNA. RNA extracted from two 
surgical biopsies of epithelial origin (mammary tumor and healthy 
skin) were used as positive controls. Mouse immunoglobulin hyper-






To verify the identity of the PCR product, all positive signals were 
purified from agarose gel by QIAquick kit (Qiagen), according to the 
 




Table 1. Clinical features of NPC patients and molecular data. 
 
Patient N° Sex Age Stage TNM Treatment CK19 RT-PCR* CK19 transcripts* 
1 F 61 IVB T4N3M0 No + + 
5 F 21 IVA T4N2M0 No - - 
6 M 76 IVB T4N3M0 No + + 
8 M 66 IVB T4N3 M0 No - - 
10 M 66 NA N0 No - - 
11 M 52 IVA T4N2cM0 No - - 
12 M 56 IVB T4N3M0 CT + - 
14 M 66 IVC M1 CT + - 
15 F 49 IVA T4N0M0 No - - 
16 M 23 IVB T4N3M0 CT+RT + - 
18 F 68 IVA T4N0M0 No - - 
23 M 73 IVC M1 CT - - 
24 M 57 III T3N2aM0 No - - 
26 M 17 IVB T3N3M0 No - - 
27 F 57 NA NA No - - 
28 M 42 NA NA No - - 
29 M 58 NA NA No + - 
30 M 16 IVA T4N0M0 No + - 
32 M 37 IVB T4N3M0 No - - 
34 M 42 III T3N0M0 RT - - 
36 M 42 NA NA No - - 
37 F 49 IVB T2N3M0 No - - 
38 M 44 IVC T3N3M1 No - - 
40 M NA NA NA No - - 
43 M 52 IVB T3N3M0 No - - 
45 M NA NA NA No - - 
46 M NA NA NA No + + 
47 M 47 IVC T4N2aM1 CT+RT + - 
48 M NA NA NA No - - 
49 M NA NA NA No + + 
 
*CK19 RT-nested PCR: +, presence of the expected 371-pb product; -, absence of the product; CK19 transcripts: +, 
presence of specific CK19 transcripts, as verified by sequencing; -, absence of CK19 transcripts detected by 




manufacturer’s instructions, and then sequenced  using the inner 
primers and the BigDye™ Terminator v3.0 DNA sequencing kit with 
the ABI PRISM 3100-Avant Genetic Analyser (Applied Biosystems). 






Clinical and pathological features 
 
We studied a cohort of 30 Tunisian patients with non 
apparent but biopsy-proven NPC. Clinical characteristics 
and stage distribution of patients are summarized in 
Table 1. Probands enrolled in the study comprised 24 
males and six females. The individual age at the moment 
of blood collection ranged from 16 to 76 with a median 
age of 46 years.  
Histologically, all tumors were undifferentiated naso-
pharyngeal carcinoma type (UCNT). Accor-ding to the 
adopted TNM classification (AJC/UICC 1986) (Bast et al., 
2003), the stage distribution at the moment of blood 
collection of the 19 NPC patients for which medical 
records were available was as follows: early stage (2 
stage III disease), advanced stage (13 stage IV A or IV B 
disease without distant metastasis, M0) and metasta-
sized (4 stage IVC, M1). Among the five treated patients 
before sample collection, 2 had confirmed distant metas-
tasis to liver or bone marrow, whereas three had loco-
regional relapse to cavum and neck. 
 
 
RNA extraction and reverse transcription 
 
Total RNA were extracted from 8 ml of peripheral blood
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Figure 2. Results of RT-PCR for CK19 in NPC patients and controls 
A. -actin in NPC patients. The 154-bp product corresponds to -actin cDNA. The 250-bp signal 
corresponds to amplification of contaminating genomic DNA.   
B. First round PCR for CK-19 in NPC patients. The expected 518-bp CK-19 PCR product is present only 
in the positive control (T(+), mammary carcinoma). No product is detected in the blood of NPC patients (Mn). 
The 773-bp signal corresponds to contaminating genomic 
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Figure 1. Results of RT-PCR for CK19 in NPC patients and controls. A) -actin in NPC 
patients: The 154-bp product corresponds to actin cDNA. The 250-bp signal corresponds 
to amplification of contaminating genomic DNA. B) First round PCR for CK-19 in NPC 
patients: The expected 518-bp CK-19 PCR product is present only in the positive control 
[T(+), mammary carc oma]. No product is det ct d in the blood of NPC patient (Mn). The 
773-bp signal corresponds to contaminating genomic DNA.C) Second round PCR for CK19 
mRNA in NPC patients. The expected 371-bp CK19 PCR product is present in the blood of 
several NPC patients (Mn), as well as in the internal positive control [T(+), mammary 
carcinoma]. The 480-bp product corresponds to RNA generated by alternative splicing. The 
600-bp corresponds to contaminating CK19 genomic DNA. D) Second round PCR for CK19 
mRNA in controls: The expected 371-bp CK-19 PCR product is present only in the positive 
control [T(+), mammary carcinoma]. No CK-19 PCR product is observed in the blood of 
healthy bone marrow donors (H1, H2 and H3). Healthy subject H2 showed the 600-bp 
contaminating genomic DNA band. M, 100 pb DNA marker (Promega); T(-), negative control 




under RNase-free conditions using TRIzole. The first 3 ml 
of blood were discarded to ensure the exclusion of 
cutaneous epithelial cells in the samples, which normally 
express the CK19 gene. RNA was also extracted from 
two fresh biopsies of epithelial origin (mammary tumor 
and healthy skin) and run as positive controls for 
detection of CK19 transcripts using our RT-PCR assay. 
The first strand of the cDNA was synthesized under 




Amplification of β-actin mRNA 
 
All specimens from NPC patients, healthy subjects, 
healthy skin biopsy and mammary tumor biopsy showed 
appropriate amplification for β-actin transcripts (154-bp 
product), ruling out the presence of specimen degra-
dation or inhibitory substances (Figure 1A). This result 
confirms the integrity of the RNA purified and the cDNA 
synthesized. Of note, an additional 250-bp product was 
shown with the expected 154-bp PCR product in some 
cases. This product was consistent with an amplification 
of the β-actin gene from genomic DNA contaminating 
some RNA preparations. This contamination was 
expected as no DNase treatment was included in our 
protocol in order to maximize the yield of RNA extracted 
from blood samples. 
 
 
Detection of CK19 transcripts in controls 
 
PCR assays for CK19 transcripts were tested first on 
cDNA obtained from reverse transcription of RNA extracted 
 




from fresh healthy skin and mammary carcinoma 
biopsies. As expected, PCR amplification using CK19 
outer primers and CK19 inner primers yielded a 518-bp 
fragment and a 371-bp fragment, respectively, both 
fragments corresponding to the CK19 cDNA, as verified 
by direct sequencing (Figure 1B and D). No PCR product 
was obtained from the cDNA of mouse immunoglobulin 
hypervariable region, confirming the specificity of the 
CK19 primers used (Figure 1B). 
 
 
Detection of CK-19 transcripts in NPC patients and 
healthy blood donors 
 
The expected 518-bp fragment at the first-round PCR 
was not detected in anyone of the healthy blood donors, 
nor NPC patients, including those having proved distant 
metastases to liver or bone marrow (Figure 1B). This was 
probably due to the rarity of epithelial neoplastic cells in 
the blood circulation at the moment of blood sample. This 
result shows the limit of the PCR sensitivity and confirms 
the necessity of a second round PCR. Of note, a 773-bp 
product was detected in 10 of the 30 tested NPC patients 
and in 1 of the 20 healthy blood donors (Figure 1B). This 
product corresponded to genomic DNA contaminating our 
RNA preparations as assessed by sequence alignment 
with the genomic sequence of CK19 (Genebank acces-
sion number NM_002276). The expected 371-bp frag-
ment at the second-round PCR was detected from PCR 
products of the first PCR reaction of 10 of the 30 tested 
NPC patients (Table 1 and Figure 1C). In contrast, no 
product was detected in blood samples from the 20 
healthy blood donors (Figure 1D). A 600-bp product was 
observed in the blood samples of 17 of the 30 NPC 
patients and in 1 of the 20 healthy blood donors 
analyzed, that corresponded to genomic DNA contami-
nation, as assessed by sequence analysis. 
 
 
Control of the specificity of the CK19 product by 
sequencing 
 
The use of CK19 as a target gene in the detection of 
circulating tumor cells is limited by the interference of 
CK19 pseudogene in RT-PCR (Ruud et al., 1999). 
Indeed, CK19 pseudogene sequence (Genebank acces-
sion number U85961) shows a high degree of identity 
with the CK19 mRNA (84.7%) which may lead to the 
amplification of a 371-bp fragment from this pseudogene 
by the inner primer CK19-3. The comparison of the 
sequence of the 371-bp fragment to the CK19 cDNA 
(Genebank accession number NM_002276) and to the 
pseudogene (Genebank accession number U85961) 
revealed that this product corresponded to pseudogene 
in 6 of the 10 positive patients, that is, 60% false positive 
rate. In the four remaining cases (M1, M6, M46, M49), 





cDNA. Thus, sequencing showed that the used nested 
RT- PCR assay may lead to false positive cases due to 
pseudogene amplification. In other hand, this amplifi-
cation may also mask the expression of CK19 mRNA 





Metastatic dissemination is a key event in the history of 
cancerous pathology because it transforms a locoer-
gional disease curable by local treatment, surgery and/or 
radiotherapy, to a widespread cancer whose treatment is 
complex and unpredictable.  
Biological heterogeneity of neoplastic cells in the 
primary and secondary tumors is the principal cause of 
treatment failure of metastases. This highlights the 
importance to understand the molecular process of 
metastase and the necessity to establish a synoptic table 
of markers which allow easy prediction, detection and 
localization of active metastasis and finally identification 
and definition of therapeutic targets. Detection of circu-
lating neoplastic cells by RT-PCR is principally based on 
selective amplification of genes that are exclusively 
expressed by these cells, but not expressed by normal 
blood cells. RNA being instable in extracellular environ-
ment, its detection indicates the presence of circulating 
living neoplastic cells in the examined blood. Many 
tumor- or organ- specific genes have been reported such 
as PSA for prostate carcinoma (Yates et al., 2012), 
mammaglobin and CK-19 for breast cancer (Chen et al., 
2010) and CEA for gastro-intestinal (Zhu et al. 2012), 
breast cancer (Chen et al., 2010) as well as for colorectal 
cancer (Jones et al., 2013). However, these tumor- or 
organ specific markers still unknown for many solid 
tumors such as the case of NPC. For this reason, 
detection of micrometastasis often targets epithelial 
genes implicated in tissue differentiation. Since cytoke-
ratin 19 is not expressed by any normal hematopoietic 
tissue, it has been reported to be the useful marker of 
occult metastasis to the peripheral blood, bone marrow 
and lymph nodes of patients with cancer of epithelial 
origin. Cytokeratins form a subgroup of intermediate 
filament protein predominantly located within cells of 
epithelial origin (Wittock et al., 2000). 
In addition to a limited number of epithelial tissues, 
CK19 expression had also been found in colon 
carcinoma, small-cell and non-small-cell lung cancer, and 
prostate cancer. These findings potentially extend the 
utility of CK19 RT-PCR as a detection assay for a broad-
spectrum of common malignancies. The aim of the 
present report was to evaluate the CK19 RT-PCR 
procedure for detecting occult metastasis in NPC, based 
on previously published assays. Using RNA extracted 
from two epithelial tissues (healthy skin biopsy and 
mammary carcinoma) as positive controls and the mouse 
immunoglobulin hypervariable region cDNA as negative 
 




























Figure 2. Schematic representation of the CK19 gene and CK19b pseudogene. 
The CK19 gene (A) and CK19b pseudogene (B) are shown with location of introns (I) and exons (E), as well as the location of 




controls of RNA purification and RT-PCR, as well as the 
blood of 20 healthy bone marrow donors as negative 
controls for specificity of the assay, we could detect the 
presence of the CK19 transcript (371-bp product) in 
epithelial tissues and its absence in the blood of all the 
healthy subjects. These results highlight the specificity of 
expression of CK19 in epithelial tissue. The specificity 
was also checked by sequencing of the PCR product. 
According to our results and those reported by Lin et al. 
(2000), the RT-nested PCR assay seemed specific to 
detect the presence of CK19 mRNA in the blood. We 
have then applied this technique to 30 Tunisian NPC 
patients with histologically proven NPC in different 
stages. Positive results were obtained for 10 of them after 
a second round PCR. The first round of PCR was 
negative for all the blood samples and the expected 
product (518-pb) was seen only for the skin biopsy. This 
is probably due to the scarcity of disseminated tumor 
cells in peripheral blood when sampling. Because the 
assay published by Lin et al. (2000) appeared to use 
specific primers for CK19, we used their exact PCR 
conditions and nested primer sets for our study. 
However, in our samples, we were not able to reproduce 
the specific bands published by Lin et al. (2000). In our 
hands, the same primer set gave rise to CK19 
pseudogene derived products in most cases, indicating 
the low robustness of the assay. 
In the present study, we encountered several difficulties 
in using CK19 as target marker. Problems we encoun-
tered were primarily due to the interference of the CK19 
pseudogene and to the unavoidable contamination of the 
RNA preparations by genomic DNA. Indeed, Ruud et al. 
(1999) have detected by RT-PCR a new pseudogene 
showing high homology to CK19 gene sequence (84.7%) 
except three small deletions and some punctual muta-
tions. In our assay, pseudogene amplification gives a 371 
bp fragment that is analogous to the product of 
amplification of the normal CK19 cDNA, with 73% of 
sequence similarity (27 nucleotide variations between the 
two products). To confirm the origin of the 371 bp 
fragment (gene or pseudogene), the nested PCR product 
of the 10 positive samples were sequenced. The com-
parison to reference sequences of CK19 cDNA 
(Genebank accession number NM_002276) and CK19 
pseudogene (Genebank accession number U85961) 
revealed that the PCR product of only four of the ten 
positive samples corresponded to the CK19 cDNA. The 
sequence of the six remaining patients was identical to 
that of the CK19 pseudogene. According to the literature 
(Goeminne et al., 2000), genomic DNA and subsequent 
pseudogene contamination is frequent in RNA prepa-
rations. Its presence could interfere and mask the CK19 
transcript in RT-PCR and sequencing. In order to improve 
the specificity of the reaction, we suggest  
designing new primers which will amplify specifically the 
CK19 cDNA. 
Notably, only 2 of the 4 NPC patients with known 
distant  metastasis were positive for the 371-bp fragment, 
 




indicating false negative results. This result was probably 
due to the absence or the rarity of neoplastic cells in the 
analyzed samples. In conclusion, we have described an 
improved RT-PCR assay that is sensitive and has high 
clinical specificity to detect minimal metastatic disease in 
patients with NPC. Nevertheless, one should be aware 
about the necessity to optimize the analytical specificity 
of the assay. Whatever the case, in its present form, the 
CK19 RT-PCR nested assay allowed identification of 
specific CK19 transcripts in the blood of at least 4 NPC 
patients. This highlights the potential interest of this 
method for the detection of subjects with subclinical 
metastasis. This assay will also facilitate the selection of 
patient suitable for adjuvant chemotherapy in order to 
eradicate micrometastasis early and enhance the cure 
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